| Name | Title | Contact Details |
|---|
Aspire General Insurance is a California-based insurance provider that specializes in private passenger auto insurance. Founded in 2012, the company operates in Arizona, California, and Michigan, offering services in both English and Spanish. Aspire has an AM Best rating of B++ (Good) with a Stable outlook, indicating its financial stability. The company focuses on liability and physical damage coverage for private passenger vehicles. It provides 24/7 claims reporting and in-house processing, along with online and mobile tools for policy management, payments, and document access. Aspire offers flexible payment options, including low down payments and installment plans. Their customer support features bilingual call centers and automated solutions for policy updates and claims tracking, ensuring a responsive service experience.
American Nation Bank is a full service community bank that serves the needs of individuals and businesses throughout Southern Oklahoma and North Texas. We provide convenient solutions for your financial needs. American Nation Bank, "Quality Banking with a Personal Touch", with locations to serve you in Ardmore, Comanche, Lone Grove and Wilson in Oklahoma and in Keller and Saginaw, Texas. We offer 7-day-a-week banking at our Homeland Banking Center in Ardmore. Member FDIC, Equal Housing Lender
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.